fluorodeoxyglucose f18 has been researched along with Budd-Chiari Syndrome in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Kesim, S; Ozguven, S | 1 |
Abadie, B; Daughters, K; Lu, S; Singh, M | 1 |
Kurtovic, J; Riordan, SM; Van Der Wall, H | 1 |
Hahm, GK; Jacobs, MP; Mantil, JC; Sizemore, AW | 1 |
4 other study(ies) available for fluorodeoxyglucose f18 and Budd-Chiari Syndrome
Article | Year |
---|---|
Budd-Chiari syndrome secondary to tumor thrombus of hepatocellular carcinoma detected by
Topics: Budd-Chiari Syndrome; Carcinoma, Hepatocellular; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Positron Emission Tomography Computed Tomography; Thrombosis | 2022 |
Budd-Chiari Syndrome Demonstrated on PET/CT.
Topics: Abdominal Pain; Budd-Chiari Syndrome; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Positron Emission Tomography Computed Tomography | 2017 |
FDG PET for discrimination between tumor extension and blood thrombus as a cause for portal vein thrombosis in hepatocellular carcinoma: important role in exclusion of transplant candidacy.
Topics: Adult; Budd-Chiari Syndrome; Carcinoma, Hepatocellular; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Liver Transplantation; Male; Patient Selection; Positron-Emission Tomography; Preoperative Care; Prognosis; Radiopharmaceuticals; Thrombosis | 2005 |
FDG uptake in inferior vena cava tumor thrombus from renal cell carcinoma on positron emission tomography.
Topics: Aged; Budd-Chiari Syndrome; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Humans; Kidney Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Vena Cava, Inferior | 2007 |